Datapoint: U.S. Supreme Court Lifts Gilenya Generics Block

The United States Supreme Court last week lifted an order that blocks generic copies of Novartis’ multiple sclerosis (MS) drug Gilenya from hitting the market. The court is still considering whether to hear the drugmaker’s patent dispute against HEC Pharm. Gilenya is a blockbuster, and Novartis’ No. 3 bestselling drug, according to data from Evaluate Pharma. For the treatment of MS, Gilenya holds covered or better status for virtually all (99%) of insured lives under the pharmacy benefit. 11.5% of covered lives have preferred access to Gilenya, growing to 47% with utilization management restrictions applied.

SOURCE: MMIT Analytics and Evaluate Pharma, as of 10/17/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: EmblemHealth Subsidiary Pulls Out of Connecticut Small Group Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today